Tafasitamab (Monjuvi)

Mechanism of action

Anti-CD19 antibody with an engineered Fc region to enhance Fcγ receptor binding affinity

Diseases for which it is used

• Diffuse large B-cell lymphoma
• Transformed lymphoma

History of changes in FDA indication

• 7/31/2020: Granted accelerated approval in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant. (Based on L-MIND)

History of changes in EMA indication

• 8/26/2021: Initial conditional approval as Minjuvi

Also known as

• Code names: MOR208, MOR00208, XmAb5574
• Generic name: tafasitamab-cxix
• Brand name: Minjuvi, Monjuvi